Deutsche Bank exercised the over-allotment option for Anthera IPO. Why didn't Deutsche Bank do the same thing as the lead underwriter for the Omeros IPO?
Anthera Pharmaceuticals Announces Closing of Underwriters' Exercise of Over-Allotment Option in Connection With Its Initial Public Offering
HAYWARD, Calif., April 6 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the closing of the underwriters' exercise of their over-allotment option to purchase an additional 604,492 shares of Anthera's common stock. The sole book-running manager of the offering is Deutsche Bank Securities Inc. Piper Jaffray & Co. is a co-lead manager of the offering and Cowen and Company, LLC and Merriman Curhan Ford & Co. are co-managers of the offering.